NRx Pharmaceuticals Begins Selling U.S.-Made, Preservative-Free Ketamine Amid Long-Running Shortage

NRx launches preservative-free ketamine and secures $11.25M for a phase 3 trial.

What the company is saying

NRx Pharmaceuticals is announcing the commercial launch of its newly approved preservative-free ketamine, manufactured in the United States, as a direct solution to a drug shortage persisting since 2018. The company emphasizes its BFS (blow-fill-seal) vial technology, which eliminates the need for needles and preservatives, positioning this as both a safety and cost advantage. NRx highlights that its veteran sales force covers approximately 80% of the US sterile injectable market, aiming for rapid market penetration. The company frames its BFS approach as a major cost-saving innovation, citing that traditional glass vial COGS can reach 70% of sales price, while BFS reduces this to under 20%. CEO Jonathan Javitt, MD, MPH, is quoted to reinforce the efficiency and market access of its sales strategy. NRx also stresses regulatory milestones: FDA approval for preservative-free ketamine, Fast Track Designation for NRX-100, Breakthrough Therapy Designation for NRX-101, and a recent $11.25 million DARPA contract for a phase 3 trial of NRX-101. The announcement projects confidence in operational execution and future market acceptance, while referencing ongoing regulatory engagement and anticipated expansion.

What the data suggests

NRx has commenced US sales of its preservative-free ketamine, a product differentiated by BFS vial technology and the absence of benzethonium chloride. The company's sales team has established relationships with purchasers controlling about 80% of the US sterile injectable market, suggesting strong initial distribution reach. Operationally, BFS manufacturing reduces cost of goods sold from 70% or more (glass vials) to below 20%, potentially restoring profitability to generic injectables. The company cites CDC data that 385,000 needlestick injuries occur annually among US hospital staff, a risk mitigated by its needle-free packaging. NRx has filed a citizen petition with the FDA to remove BZT from ketamine, supported by a public toxicology report. The product's two-year shelf life compares favorably to the 90-day limit for compounded alternatives, and NRx anticipates extending this. The company has contracted with German suppliers to double its BFS manufacturing capacity in South Carolina. In October 2026, NRx was awarded an $11.25 million DARPA contract for a phase 3 trial of NRX-101, combining D-cycloserine/lurasidone with robotic neuronavigated TMS for depression. NRX-100 and NRX-101 have received Fast Track and Breakthrough Therapy Designations, respectively. No actual revenue, profit, or cash flow figures are disclosed, and customer willingness for long-term agreements is asserted but not quantified.

Analysis

The announcement is generally positive in tone, highlighting the commercial launch of a newly approved product, regulatory milestones, and operational expansion. The commencement of sales for the preservative-free ketamine is a realised fact, as are the regulatory designations for NRX-100 and NRX-101. However, several claims are forward-looking or aspirational, such as anticipated market acceptance, extension of product expiration, and potential for additional products. The expansion of manufacturing capacity is disclosed as a contracted initiative, but no immediate financial impact or profitability metrics are provided. The capital intensity flag is triggered by the mention of doubling manufacturing footprint, which implies significant investment with benefits that are not immediate. The gap between narrative and evidence is most apparent in the forward-looking statements about market adoption and future product extensions, which are not yet realised. The data supports operational progress but lacks financial disclosure, capping the signal at weak_positive.

Risk flags

• ●The company does not disclose actual revenue, profit, or cash flow figures from the ketamine launch, limiting visibility into near-term financial impact and making it difficult to assess commercial traction.
• ●While NRx claims its sales force covers 80% of the market, there is no evidence of signed customer agreements or committed purchase volumes, introducing uncertainty about actual uptake and revenue realization.
• ●The expansion of BFS manufacturing capacity in South Carolina is described as contracted but lacks detail on timeline, capital outlay, or operational ramp-up, raising execution risk for scaling production.
• ●The $11.25 million DARPA contract funds a phase 3 trial for NRX-101, but clinical development carries inherent risk, including trial failure, regulatory hurdles, and delayed or uncertain commercialization.
• ●NRx's advocacy for the removal of BZT from ketamine via FDA petition is ongoing, and regulatory outcomes are unpredictable, potentially affecting the competitive landscape and product adoption.

Bottom line

NRx Pharmaceuticals has begun US sales of its preservative-free ketamine, leveraging BFS technology to reduce costs and improve safety, but has not disclosed actual sales or revenue figures. The company claims broad market access through its sales team and is investing in manufacturing expansion, though timelines and financial details are sparse. The $11.25 million DARPA contract for a phase 3 trial of NRX-101 is a significant non-dilutive funding milestone, but clinical and regulatory risks remain. While the operational and regulatory achievements are credible, the absence of financial metrics and customer commitments leaves the commercial impact unproven. Investors should watch for concrete sales data, execution of manufacturing scale-up, and progress on clinical and regulatory milestones. The key takeaway is that NRx is moving from development to commercialization, but proof of market traction and financial performance is still pending.

Announcement summary

(NASDAQ:NRXP) NRx Pharmaceuticals, Inc. announced it has commenced sales of its newly approved preservative-free ketamine, which is manufactured in the United States and addresses a drug shortage that has persisted since 2018. The company's injectable ketamine is preservative-free, does not contain benzethonium chloride (BZT), and is delivered in a needle-free blow-fill-seal (BFS) vial with a luer-lock tip for direct syringe attachment. NRx's sales team consists of veteran representatives with established relationships covering approximately 80% of the current US sterile injectable market. The company has focused on converting sterile injectable products from traditional glass bottles to BFS technology, which offers manufacturing and cost-of-goods-sold (COGS) efficiencies. NRx's prior experience during Covid highlighted that glass vial COGS may represent 70% or more of the sales price to hospitals, while BFS reduces COGS to less than 20%. The BFS vial eliminates the need for needles, reducing staff time and the risk of needlestick injuries, which the CDC estimates at approximately 385,000 incidents per year among hospital-based healthcare personnel in the United States. The NRx luer vial also avoids generating sharps medical waste. NRx has filed a citizen petition with the FDA to remove BZT from ketamine and has made an expert toxicology report available on the FDA docket, documenting that patients may be exposed to BZT levels exceeding the FDA's published maximum daily intravenous injection exposure of 1 milligram. Customers have indicated willingness to enter long-term agreements for guaranteed supply, as compounded sterile products are limited to a 90-day maximum beyond use date in most states, compared to an initial two-year expiration for the NRx product, which the company anticipates extending. NRx has contracted with German manufacturers of BFS technology to double its manufacturing footprint in South Carolina. In October 2026, the Defense Advanced Research Projects Agency awarded NRx an $11.25 million contract to conduct a phase 3 trial of its oral drug NRX-101 (D-cycloserine/lurasidone) combined with Robotic Neuronavigated Transcranial Magnetic Stimulation as a one-day treatment for depression. NRX-100 has received Fast Track Designation for the treatment of suicidal ideation in depression, including bipolar depression. NRX-101 has been awarded Breakthrough Therapy Designation for the treatment of suicidal bipolar depression.

Disagree with this article?